Shalby Ltd. · NSE:SHALBY
Shalby — Q3 FY2018 Earnings Presentation
16 slides from Shalby's earnings presentation, January 2018
Slide 1: Financial Results Review Q3 FY2018 and YTD ended 31.12.17
Financial Results Review Q3 FY2018 and YTD ended 31.12.17 1
Slide 2: Operational Performance Synopsis
Operational Performance Synopsis (INR in million) Quarter Ended Quarter Ended Particulars 31-12-17 % of Revenue 31-12-16 % of Revenue Growth Total Revenue 1019.99 100% 769.81 100% 32.50% Total EBITDA 257.55 25.25% 203.00 26.37% 26.87% Bed Capacity (Nos.) 2,012 1,215 65.60% Operational Beds (Nos.) 95
Slide 3: Financial Highlights Q3FY18
Financial Highlights Q3FY18 (INR in million) Particular Quarter Ended 31- Quarter Ended 31- 12-17 % of Revenue 12-16 % of Revenue Growth Variation Revenue from Operations 1,005.95 100.0% 752.51 100.0% 33.7% Expenses Materials & Consumables 276.71 27.5% 177.45 23.6% 55.9% 3.9% Fees to Doctors and Con
Slide 4: Financial Performance Comparison
Financial Performance Comparison Normalized PAT (in millions) Operational EBITDA (in millions) EBITDA Margin Normalized PAT Margin 243.50 25.64% 107.84 24.21% 192.98 10.60% 8.80% 67.15 Q3FY17 Q3FY18 Q3FY17 Q3FY18 • Operational EBITDA grew by 26.2% due to increase in • Normalized PAT grew by 60.6% re
Slide 5: Operational Performance Synopsis
Operational Performance Synopsis (INR in million) Particulars YTD Dec’17 % of Revenue YTD Dec’16 % of Revenue Growth Total Revenue 2831.99 100% 2416.15 100% 17.21% Total EBITDA 758.58 26.79% 579.76 24.00% 30.84% Bed Capacity (Nos.) 2,012 1,215 65.60% Operational Beds (Nos.) 951 762 24.80% Average Le
Slide 6: Financial Highlights YTD Dec'17
Financial Highlights YTD Dec’17 (INR in million) Particular YTD Dec’17 % of Revenue YTD Dec’16 % of Revenue Growth Variation Revenue from Operations 2,809.84 100.00% 2,388.65 100.00% 17.63% Expenses Materials & Consumables 728.72 25.93% 633.98 26.54% 14.94% (0.61)% Fees to Doctors and Consultants 59
Slide 7: Revenue Composition (9M FY18)
Revenue Composition (9M FY18) Specialty Mix Payee Profile 2.0% 14.9% 14.4% 4.2% 5.9% 9.0% 55.9% 24.6% 58.5% 10.6% Arthroplasty General Medicine & Critical Care Cardiac Sciences Other Ortho Selfpay TPA Corp-Govt Corp-Private Onco Sciences Others 7
Slide 8: Revenue Composition & Cost Structure
Revenue Composition & Cost Structure Revenue Mix Cost Structure Knee Replacement Others EBITDA Margin Administrative and Other Expenses Employee Benefit Expenses Other Operative Costs Fees to Doctors and Consultants Materials & Consumables 39.70% 37.67% 40.46% 48.02% 24.50% 19.11% 22.24% 26.22% 7.98
Slide 9: Maturity Profile (9M FY18)
Maturity Profile (9M FY18) % of % of Maturity Operational Operational Operational Occupancy ALOS (Days) Bed Capacity Stage Beds Revenue Beds 5 years + 63% 44% 414 41% 4.03 594 (SG; Vijay; Krishna; Vapi) 2-5 years 22% (Jabalpur, Indore) 31% 293 36% 3.48 476 11% 20% < 2 years (Jaipur; Naroda; 194 23%
Slide 10: Performance Analysis
Performance Analysis Revenue from Operations (in millions) Operational EBITDA (in millions) EBITDA Margin Revenue Growth YoY 735 736 3,240 695 17.63% 2,868 26.44% 26.21% 2,810 576 2,627 22.68% 20.09% 12.95% 8.94% 9.17% FY15 FY16 FY17 9mFY18 FY15 FY16 FY17 9mFY18 10
Slide 11: Operational Metrics
Operational Metrics Bed Capacity Operational Beds FY15 FY16 FY17 9mFY18 FY15 FY16 FY17 9mFY18 951 2,012 2,012 823 781 1,295 593 907 FY15 FY16 FY17 9mFY18 FY15 FY16 FY17 9mFY18 11
Slide 12: Operational Metrics
Operational Metrics Occupied Beds ALOS (Days) ARPOB Occupancy % 4.14 324 39,904 271 34,173 33,032 4.03 40.95% 32,495 252 36.47% 3.99 34.48% 196 31.75% 3.76 FY15 FY16 FY17 9mFY18 FY15 FY16 FY17 9mFY18 12
Slide 13: Key Developments
Key Developments Historically highest revenue during the quarter Successful conclusion of the IPO of INR 5,048 million and listing on the stock exchanges Surat and Naroda units operationalized in Q2FY18 13
Slide 14: Shareholding Pattern
Shareholding Pattern Shareholding as on 31st December 2017 Trust Others 0.94% 0.01% FIIs/ DIIs and Retail 19.65% FIIs – 6.64% DIIs – 5.18% Retail – 7.83% Promoter 79.41% Total Number of Shares: 108,009,770 14
Slide 15: Important Disclaimer
Important Disclaimer No representation or warranty, express or implied is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of such information or opinions contained herein. The information contained in this presentation is only current as of its da
Slide 16: Thank You
SHALBY meee Thank You